These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 14623063)

  • 21. Effects of the phytoestrogen genistein on the circulating soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin system in early postmenopausal women.
    Crisafulli A; Altavilla D; Squadrito G; Romeo A; Adamo EB; Marini R; Inferrera MA; Marini H; Bitto A; D'Anna R; Corrado F; Bartolone S; Frisina N; Squadrito F
    J Clin Endocrinol Metab; 2004 Jan; 89(1):188-92. PubMed ID: 14715848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized placebo-controlled trial of short-term graded transdermal estradiol in healthy gonadotropin-releasing hormone agonist-suppressed pre- and postmenopausal women: effects on serum markers of bone turnover, insulin-like growth factor-I, and osteoclastogenic mediators.
    Liu PY; Hoey KA; Mielke KL; Veldhuis JD; Khosla S
    J Clin Endocrinol Metab; 2005 Apr; 90(4):1953-60. PubMed ID: 15623811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women.
    Mezquita-Raya P; de la Higuera M; García DF; Alonso G; Ruiz-Requena ME; de Dios Luna J; Escobar-Jiménez F; Muñoz-Torres M
    Osteoporos Int; 2005 Nov; 16(11):1368-74. PubMed ID: 15711777
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20-75.
    Liu JM; Zhao HY; Ning G; Zhao YJ; Chen Y; Zhang Zh; Sun LH; Xu MY; Chen JL
    Calcif Tissue Int; 2005 Jan; 76(1):1-6. PubMed ID: 15455183
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased serum osteoprotegerin values in long-lived subjects: different effects of inflammation and bone metabolism.
    Mazziotti G; Amato G; Sorvillo F; Piscopo M; Rizzo MR; Lalli E; Iride L; Cioffi M; Molinari AM; Paolisso G; Carella C
    Eur J Endocrinol; 2006 Mar; 154(3):373-7. PubMed ID: 16498049
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased levels of osteoprotegerin in hemodialysis patients.
    Avbersek-Luznik I; Malesic I; Rus I; Marc J
    Clin Chem Lab Med; 2002 Oct; 40(10):1019-23. PubMed ID: 12476941
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The relationships between changes of serum osteoprotegerin, nuclear factor-kappa B ligand receptor activator, and age, menopause, bone biochemical markers and bone mineral densities in women aged 20 - 75].
    Liu JM; Zhao HY; Ning G; Zhao YJ; Chen Y; Zhang LZ; Xu MY; Chen JL
    Zhonghua Nei Ke Za Zhi; 2004 Jun; 43(6):447-50. PubMed ID: 15312444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins.
    Abrahamsen B; Hjelmborg JV; Kostenuik P; Stilgren LS; Kyvik K; Adamu S; Brixen K; Langdahl BL
    Bone; 2005 Apr; 36(4):727-35. PubMed ID: 15781001
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess--possible role in bone homeostasis.
    Ueland T; Bollerslev J; Godang K; Müller F; Frøland SS; Aukrust P
    Eur J Endocrinol; 2001 Dec; 145(6):685-90. PubMed ID: 11720891
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in osteoprotegerin and markers of bone metabolism during glucocorticoid treatment in patients with chronic glomerulonephritis.
    Sasaki N; Kusano E; Ando Y; Nemoto J; Iimura O; Ito C; Takeda S; Yano K; Tsuda E; Asano Y
    Bone; 2002 Jun; 30(6):853-8. PubMed ID: 12052453
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in the serum growth factors and osteoprotegerin after bone marrow transplantation: impact on bone and mineral metabolism.
    Baek KH; Lee WY; Oh KW; Kim HS; Han JH; Kang MI; Cha BY; Lee KW; Son HY; Kang SK; Kim CC
    J Clin Endocrinol Metab; 2004 Mar; 89(3):1246-54. PubMed ID: 15001618
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis.
    Franck H; Meurer T; Hofbauer LC
    J Rheumatol; 2004 Nov; 31(11):2236-41. PubMed ID: 15517638
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum osteoprotegerin and renal osteodystrophy.
    Coen G; Ballanti P; Balducci A; Calabria S; Fischer MS; Jankovic L; Manni M; Morosetti M; Moscaritolo E; Sardella D; Bonucci E
    Nephrol Dial Transplant; 2002 Feb; 17(2):233-8. PubMed ID: 11812872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circulating osteoprotegerin levels are associated with age, waist-to-hip ratio, serum total cholesterol, and low-density lipoprotein cholesterol levels in healthy Korean women.
    Oh ES; Rhee EJ; Oh KW; Lee WY; Baek KH; Yoon KH; Kang MI; Yun EJ; Park CY; Choi MG; Yoo HJ; Park SW
    Metabolism; 2005 Jan; 54(1):49-54. PubMed ID: 15562379
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women.
    Kim JG; Kim JH; Lee DO; Kim H; Kim JY; Suh CS; Kim SH; Choi YM
    Menopause; 2008; 15(2):357-62. PubMed ID: 17925661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients.
    Seminari E; Castagna A; Soldarini A; Galli L; Fusetti G; Dorigatti F; Hasson H; Danise A; Guffanti M; Lazzarin A; Rubinacci A
    HIV Med; 2005 May; 6(3):145-50. PubMed ID: 15876279
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
    Dobnig H; Hofbauer LC; Viereck V; Obermayer-Pietsch B; Fahrleitner-Pammer A
    Osteoporos Int; 2006; 17(5):693-703. PubMed ID: 16435076
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men.
    Khosla S; Atkinson EJ; Dunstan CR; O'Fallon WM
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1550-4. PubMed ID: 11932280
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) on the decrease of bone mineral density.
    Suzuki K; Kurose T; Takizawa M; Maruyama M; Ushikawa K; Kikuyama M; Sugimoto C; Seino Y; Nagamatsu S; Ishida H
    Diabetes Res Clin Pract; 2005 May; 68(2):117-25. PubMed ID: 15860239
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GH replacement therapy increases plasma osteoprotegerin levels in GH-deficient adults.
    Lanzi R; Losa M; Villa I; Gatti E; Sirtori M; Dal Fiume C; Rubinacci A
    Eur J Endocrinol; 2003 Feb; 148(2):185-91. PubMed ID: 12590637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.